Education
About Us
Working with TipRanks
Follow Us
Nkarta (NKTX)
NASDAQ:NKTX
NKTX Stock Chart & Stats
$2.07
-$0.05(-2.07%)
At close: 4:00 PM EST
$2.07
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.31 - $2.74
Previous CloseN/A
Volume369.36K
Average Volume (3M)612.23K
Market Cap
$147.03M
Enterprise Value-$52.47M
Total Cash (Recent Filing)$282.33M
Total Debt (Recent Filing)$76.63M
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,029,510
10 Day Avg. Volume602,298
30 Day Avg. Volume612,228
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.62
Enterprise Value/Market Cap-0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$12.33Price Target Upside495.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And Funding VisibilityAnalyst points out that about $317 million in cash provides a multi year runway, offering funding visibility to support operations through upcoming proof of concept readouts in autoimmune indications.
Conditioning Regimen EfficacyAnalyst highlights that adopting a fludarabine plus cyclophosphamide lymphodepletion regimen produced complete B cell depletion in treated patients, supporting protocol adoption and likely improving trial outcomes and enrollment.
Regulatory And Trial DesignAnalyst notes FDA agreement to remove the patient-by-patient stagger and allow conventional dose escalation under a combined safety board, enabling multiple patients to be dosed simultaneously and accelerating enrollment across indications.
Bears Say
Financial Performance And Cash BurnAnalyst observes that a reported quarterly net loss of $21.7 million, or $0.29 per share, underscores ongoing cash burn and the need to manage operating expenses.
Protocol Adjustments And Prior EfficacyAnalyst notes that the shift to a fludarabine plus cyclophosphamide conditioning was prompted by incomplete B cell depletion with the prior regimen, indicating earlier protocol inefficacy and potential need for further adjustments.
Safety Risk — B Cell AplasiaAnalyst warns that company disclosure of deep B cell aplasia in some patients raises safety concerns that could increase monitoring, treatment burden, and regulatory scrutiny.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.31 and its highest was $2.74 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $147.03M.
When is Nkarta’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nkarta’s earnings last quarter?
Currently, no data Available
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nkarta have?
Nkarta has 71,029,510 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (495.65% Upside)
$12.33 (495.65% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 92.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.96%
12-Months-Change
Fundamentals
Return on Equity
-26.69%
Trailing 12-Months
Asset Growth
-19.70%
Trailing 12-Months
Company Description
Nkarta
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$12.33
▲(495.65% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---